Skip to main content
Category

Research

Science Direct
ResearchTreatments

Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with Atypical EGFR Activating Mutations: A Retrospective Multicenter Study

*January 2023* Introduction Epidermal growth factor receptor (EGFR) mutations drive a subset of non-small cell lung cancer (NSCLC). Patients harboring the common EGFR mutations, deletion of exon 19 (Ex19del) and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. However, the effect of osimertinib on NSCLC with atypical EGFR…
laurabbook@gmail.com
February 6, 2023
Medpage Today ASCO Reading Room
ResearchTreatments

New Treatment Options for Stage IV NSCLC With Driver Alterations

*January 2023* The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies -- DESTINY-Lung01 and CodeBreaK100 -- incorporated into the guidance. In the update, published in the Journal of Clinical Oncology, Dwight H. Owen, MD, MS, of the Ohio State University in Columbus,…
laurabbook@gmail.com
February 3, 2023
JTO Clinical and Research Reports
ResearchTreatments

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

*November 2022* Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable…
laurabbook@gmail.com
February 3, 2023
Targeted Oncology
ResearchTreatments

Newer Targets in NSCLC Lead to Directed Therapies

*December 2022* In non–small cell lung cancer, EGFR mutations, MET exon 14 skipping mutations, and HER2 mutations are common mutations for which directed therapies are available. New approaches and novel agents are constantly being developed to identify and treat emerging targets in non– small cell lung cancer (NSCLC). This article…
laurabbook@gmail.com
February 3, 2023
JTO Clinical and Research Reports
ResearchTreatments

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

*October 2022* Introduction There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combination in relation to chemotherapy alone in this patient population.…
laurabbook@gmail.com
February 3, 2023